Kyverna Therapeutics, Inc. KYTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $126.36M-5.5% | $133.72M-2.5% | $137.19M+0.9% | $135.93M+6.7% | $127.43M+13.3% | ||
| $37.43M+3.7% | $36.11M+5.0% | $34.4M-3.7% | $35.7M+7.5% | $33.22M+10.3% | ||
| $163.79M-3.6% | $169.83M-1.0% | $171.59M0.0% | $171.63M+6.8% | $160.65M+12.7% | ||
| -$163.79M+3.6% | -$169.83M+1.0% | -$171.59M0.0% | -$171.63M-6.8% | -$160.65M-12.7% | ||
| $1.13M+131% | $490K+571% | $73K-25.5% | $98K-20.3% | $123K-13.4% | ||
| $7.39M-13.3% | $8.52M-19.6% | $10.59M-18.1% | $12.93M-15.1% | $15.24M+0.7% | ||
| -$156.4M+3.0% | -$161.31M-0.2% | -$160.99M-1.4% | -$158.7M-9.1% | -$145.42M-14.1% | ||
| -$3.27+10.2% | -$3.64+2.4% | -$3.73-1.4% | -$3.68-8.9% | -$3.38+2.6% | ||
| -$162.14M+3.5% | -$168.03M+0.9% | -$169.59M-0.1% | -$169.49M-6.9% | -$158.5M-12.8% | ||
| -$163.79M+3.6% | -$169.83M+1.0% | -$171.59M0.0% | -$171.63M-6.8% | -$160.65M-12.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kyverna Therapeutics, Inc. profitable?
- Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s earnings per share?
- Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.
- Where does Kyverna Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.